This site contains materials related to Novo Nordisk scientific presentations at the Advanced Technologies & Treatments for Diabetes (ATTD) 2020 congress. The information on this site is intended for Healthcare Providers only and may relate to data concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. The information contained in this site is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product. Furthermore, it is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation.

The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have any questions regarding any information contained on this site you should consult a physician.

Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this website.

I have read and accept the legal notice for Novo Nordisk scientific presentations at ATTD 2020.

 Accept  Decline

Reduced number of hypoglycaemic events observed in children after introducing connected insulin pens

P Adolfsson,1 V Björnsson,1 NV Hartvig,2 A Kaas,3 J Møller,4 E Ogionwo Lange1

1Department of Pediatrics, Kungsbacka Hospital, Kungsbacka, Sweden; 2Novo Nordisk A/S, Global Development, Data Science, Søborg, Denmark; 3Novo Nordisk A/S, Global Development, Medical & Science Digital Health, Søborg, Denmark; 4Novo Nordisk A/S, Global Development, Partnerships & Commercial Strategy, Søborg, Denmar

 

View Presentation

 

View Presentation

Share this Presentation via Email

Video

Presentation Slides

References
(1) Adolfsson P et al. Poster 1076-P presented at 79th Scientific Sessions of the American Diabetes Association, 7–11 June 2019, San Francisco, CA, USA;
(1) Adolfsson P et al. Poster 126-LB presented at 79th Scientific Sessions of the American Diabetes Association, 7–11 June 2019, San Francisco, CA, USA.